Telmisartan, a prescription blood pressure medication, draws longevity interest for partial effects on sugar and fat handling. Evidence is strongest for lowering raised blood pressure and urine protein. It protected high-risk people about as well as an older heart-protective drug, but not clearly beyond inactive treatment. Metabolic gains are small. Main risks are dizziness, high blood potassium, a dip in kidney filtering and serious harm to an unborn baby. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure (home, seated and standing) | Below 130/80 mmHg | Expected to change; hypotension safety check |
| Serum potassium | 4.0–5.0 mmol/L | Safety check |
| Serum creatinine and eGFR | Creatinine about 0.6–1.3 mg/dL; eGFR tracked against own baseline | Safety check |
| UACR | Below 30 mg/g | Expected to fall |
| Fasting glucose and HbA1c | Fasting glucose below 100 mg/dL; HbA1c below 5.7% | Expected to change modestly |
| Digoxin or lithium level (if taking) | Not specified in the ER | Drug-level check |
| Pregnancy test (women who could become pregnant) | Not specified in the ER | Baseline check |
Cadence: Potassium and creatinine 1–2 weeks after starting or each dose increase; blood pressure daily for the first 2–4 weeks; potassium, creatinine, eGFR and UACR at 3 months and every 6–12 months; HbA1c and fasting glucose every 6–12 months; sooner after illness, dehydration or new interacting drugs